Intellia Therapeutics, Inc.
Pembelian
Diupdate

NTLA - Inverse head & shoulders

175
An inverse head & shoulders pattern formed in the charts of Intellia, a company developing CRISPR gene-editing therapy. While CRISPR has not been approved to begin human trials in the US, it has already been tested on over 80 patients in China.

Target: $31 (previous closing high), or long term hold
Stop: $18 - $20
Catatan
Note: 2 other companies also developing CRISPR-Cas9 tech are CRSP and EDIT. Their stocks have skyrocketed the past month. It is advisable to wait for a correction before taking a position on them.
Trading ditutup: target tercapai
It wasn't a straightforward journey, but got there on time anyway! I hope everyone reading took profits at $31 (or even higher)

Pernyataan Penyangkalan

Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.